Clinical Research
Copyright ©The Author(s) 2004. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 1, 2004; 10(23): 3506-3510
Published online Dec 1, 2004. doi: 10.3748/wjg.v10.i23.3506
HDR-192Ir intraluminal brachytherapy in treatment of malignant obstructive jaundice
Yi Chen, Xiao-Lin Wang, Zhi-Ping Yan, Jie-Min Cheng, Jian-Hua Wang, Gao-Quan Gong, Sheng Qian, Jian-Jun Luo, Qing-Xin Liu
Yi Chen, Xiao-Lin Wang, Zhi-Ping Yan, Jie-Min Cheng, Jian-Hua Wang, Gao-Quan Gong, Sheng Qian, Jian-Jun Luo, Qing-Xin Liu, Department of Radiology, Affiliated Zhongshan Hospital, Medical Center of Fudan University, Shanghai 200032, China
Author contributions: All authors contributed equally to the work.
Correspondence to: Dr. Yi Chen, Department of Radiology, Affiliated Zhongshan Hospital, Medical Center of Fudan University, 180 Fenglin Road, Shanghai 200032, China
Telephone: +86-21-64041990 Ext. 2533
Received: January 10, 2004
Revised: January 22, 2004
Accepted: March 24, 2004
Published online: December 1, 2004
Abstract

AIM: To determine the feasibility and safety of intraluminal brachytherapy in treatment of malignant obstructive jaundice (MOJ) and to evaluate the clinical effect of intraluminal brachytherapy on stent patency and patient survival.

METHODS: Thirty-four patients with MOJ were included in this study. Having biliary stent placed, all patients were classified into intraluminal brachytherapy group (group A, n = 14) and control group (group B, n = 20) according to their own choice. Intraluminal brachytherapy regimen included: HDR-192Ir was used in the therapy, fractional doses of 4-7 Gy were given every 3-6 d for 3-4 times, and standard points were established at 0.5-1.0 cm. Some patients of both groups received transcatheter arterial chemoembolization (TACE) after stent placement.

RESULTS: In group A, the success rate of intraluminal brachytherapy was 98.0%, RTOG grade 1 acute radiation morbidity occurred in 3 patients, RTOG/EORTC grade 1 late radiation morbidity occurred in 1 patient. Mean stent patency of group A (12.6 mo) was significantly longer than that of group B (8.3 mo) (P < 0.05). There was no significant difference in the mean survival (9.4 mo vs 6.0 mo) between the two groups.

CONCLUSION: HDR-192Ir intraluminal brachytherapy is a safe palliative therapy in treating MOJ, and it may prolong stent patency and has the potentiality of extending survival of patients with MOJ.

Keywords: $[Keywords]